Johnson & Johnson (JNJ): Price and Financial Metrics


Johnson & Johnson (JNJ)

Today's Latest Price: $160.30 USD

0.35 (-0.22%)

Updated Jan 15 7:00pm

Add JNJ to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

JNJ Stock Summary

  • With a market capitalization of $422,917,980,257, Johnson & Johnson has a greater market value than 99.77% of US stocks.
  • Johnson & Johnson's stock had its IPO on January 1, 1986, making it an older stock than 92.8% of US equities in our set.
  • The volatility of Johnson & Johnson's share price is greater than that of just 0.18% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Johnson & Johnson, a group of peers worth examining would be WMT, JPM, V, PG, and UNH.
  • JNJ's SEC filings can be seen here. And to visit Johnson & Johnson's official web site, go to www.jnj.com.

JNJ Stock Price Chart Interactive Chart >

Price chart for JNJ

JNJ Price/Volume Stats

Current price $160.30 52-week high $161.95
Prev. close $160.65 52-week low $109.16
Day low $159.10 Volume 7,630,800
Day high $161.40 Avg. volume 8,384,970
50-day MA $151.13 Dividend yield 2.52%
200-day MA $147.79 Market Cap 422.00B

Johnson & Johnson (JNJ) Company Bio


Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.

JNJ Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$160.30$64.67 -60%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Johnson & Johnson. To summarize, we found that Johnson & Johnson ranked in the 31th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Johnson & Johnson, consider:

  • The company has produced more trailing twelve month cash flow than 97.59% of its sector Healthcare.
  • The business' balance sheet reveals debt to be 8% of the company's capital (with equity being the remaining amount). Approximately just 22.84% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 37.74% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-60%
1%-60%
2%-60%
3%-59%
4%-59%
5%-58%

Want more companies with a valuation profile/forecast similar to that of Johnson & Johnson? See BAX, ICLR, BIO, HOLX, and LNTH.


JNJ Latest News Stream


Event/Time News Detail
Loading, please wait...

JNJ Latest Social Stream


Loading social stream, please wait...

View Full JNJ Social Stream

Latest JNJ News From Around the Web

Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

These are the known side effects of the newest coronavirus vaccine

The rollout of the coronavirus vaccine continues to be a bit bumpy in the US, bogged down by everything from states having complex recipient tiers to follow, to supply limits. President-elect Joe Biden delivered remarks on Friday that laid out his plan to significantly improve the COVID vaccine rollout after next week, when he and Vice President-elect Kamala Harris take office. Meanwhile, interim findings associated with Johnson & Johnson's coronavirus vaccine trial show significant promise, suggesting that yet another COVID vaccine will receive authorization in the US soon. News surrounding the coronavirus vaccine continues to mount, with the end of the week bringing a number of new developments -- including the Trump administration misleading the nation about the size of the US vaccin...

BGR | January 16, 2021

CES showed off the COVID-19 mask gimmick arms race

Flashy masks won’t keep everyone safe from COVID-19. Other news includes early reports on the Johnson & Johnson coronavirus vaccine and the contagious variants.

The Verge | January 16, 2021

Knee Implants Market 2026: Industry Analysis, Outlook and Forecast Research Report: Top Key Players are B. Braun, Smith & Nephew, Zimmer Biomet Holding Inc., Stryker, Exactech, Johnson & Johnson, DJO Surgical, Medtronic, Becton Dickinson

ReportsnReports.com the exclusive leading provider of market research reports published research report on “Global Knee Implants Market Research Report 2020”. The Global Knee Implants Market Report is a professional and in-depth study on the current state of the Knee Implants Market. The

OpenPR | January 16, 2021

Johnson & Johnson reveals the results of the COVID vaccine trials

The drug in clinical trials has shown up to 100% efficacy with side effects comparable to other vaccines. The anti-coronavirus vaccine candidate Ad26.COV2.S from Johnson & Johnson (developed by its subsidiary, Janssen) has successfully completed phase I / IIa clinical trials. The research results are published in the New England Journal of Medicine. It is noted […] For more stories like Johnson & Johnson reveals the results of the COVID vaccine trials , please click here Revyuh .

Revyuh | January 15, 2021

Pharma and OTC Market May See a Big Move | Endo, Johnson & Johnson, Takeda

COVID-19 Outbreak-Global Pharma and OTC Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support.

OpenPR | January 15, 2021

Read More 'JNJ' Stories Here

JNJ Price Returns

1-mo 3.75%
3-mo 12.15%
6-mo 8.61%
1-year N/A
3-year 18.00%
5-year 91.22%
YTD 1.86%
2020 10.82%
2019 16.22%
2018 -5.13%
2017 24.43%
2016 15.33%

JNJ Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full JNJ Dividend History

Continue Researching JNJ

Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:

Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8846 seconds.